Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognizing its innovative approach to addressing cancer drug resistance. The award underscores the company's strategy of developing resistance-modulating treatments, including its lead candidate ENV-105 (carotuximab), designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies.
The Pinnacle Awards, which celebrate excellence in healthcare innovation, have selected Kairos Pharma for its work in targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs.
"We are honored to receive this recognition from the Pinnacle Awards," said Dr. John S. Yu, CEO of Kairos Pharma. "This award validates our mission to overcome drug resistance and improve outcomes for cancer patients. Our focus on resistance-modulating therapies represents a paradigm shift in oncology, offering hope for more durable responses." The company's approach is based on structural biology, aiming to overcome both drug resistance and immune suppression in cancer.
The importance of this announcement lies in the growing challenge of cancer drug resistance, which limits the effectiveness of many standard treatments. By targeting resistance pathways, Kairos Pharma's ENV-105 has the potential to enhance the efficacy of existing therapies, potentially improving survival rates and quality of life for patients. The company's ongoing clinical trials are critical steps toward bringing this therapy to market.
For more information about Kairos Pharma and its pipeline, visit the company's newsroom at https://ibn.fm/KAPA. The full press release detailing the award can be accessed at https://ibn.fm/ghPJC.
Kairos Pharma Ltd., based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
